Posted on February 2, 2016 by Sitemaster
Some 2½ years ago, James presented data from the TRAPEZE trial at the annual meeting of the American Society of Clinical Oncology in Chicago. At the time, we described these data as “unsurprising.” … READ MORE …
Filed under: Management, Treatment | Tagged: catration-resistant, docetaxel, mCRPC, metastatic, outcome, strontium-89, TRAPEZE, zoledronic acid | Leave a comment »
Posted on January 5, 2016 by Sitemaster
In a poster presentation to be given at the upcoming Genitourinary Cancers Symposium in San Francisco later this week, data from the STAMPEDE trial in the UK appear to have demonstrated a result that few people seem to have expected. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", celecoxib, metastatic, outcome, STAMPEDE, Treatment, zoledronic acid | 4 Comments »
Posted on June 2, 2013 by Sitemaster
The only late-breaking, prostate cancer-specific paper to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) this year was from the TRAPEZE study carried out in the UK. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, chemotherapy, docetaxel, mCRPC, metastatic, strontium-89, TRAPEZE, zoledronic acid | 2 Comments »
Posted on March 4, 2011 by Sitemaster
Full data from the randomized, double-blind, multi-center, Phase III clinical trial comparing denosumab to zoledronic acid in the prevention of skeletal-related events in men with castration-resistant prostate cancer (CRPC) has now been published in The Lancet. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: denosumab, Prevention, skeletal-related event, SRE, zoledronic acid | Leave a comment »
Posted on July 12, 2009 by Sitemaster
This weekend’s news reports deal with:
- A new epidemiological database for prostate cancer research
- Phase II trial results for the “vaccine” PSA: 154-163 (155L)
- The degree to which adding hormone therapy to radiotherapy affects outcomes in patients with localized prostate cancer
- The possibility that zoledronic acid could be used just once a year to prevent bone loss and related events in men having androgen deprivation therapy … READ MORE …
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: epidemiology, hormone therapy, PSA: 154-163 (155L), radiotherapy, zoledronic acid | 5 Comments »
Posted on September 1, 2008 by Sitemaster
In today’s reports:
- Zoledronic acid (Zometa) has confirmed it’s impact on skeletal strength in the “real world”
- Time to recovered of “normal” testosterone levels after ADT has been measured in a prospective clinical trial
- Acupuncture appear to work to relieve “hot flashes” in men on LHRH agonists … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acupuncture, cancer, hormone, news, prostate, testosterone, therapy, update, zoledronic acid | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 